MSLN and ovarian carcinoma: In 2014, Yuan et al. constructed a fusion protein consisting of HSP70 plus a single-chain antibody variable fragment which makes the protein specifically target mesothelin-expressing tumors such as mesothelioma or ovarian cancer.